Search results for " Corticosteroid"

showing 10 items of 53 documents

Withdrawal of inhaled corticosteroids in COPD: A meta-analysis

2017

Background Conflicting findings exist on the benefit of withdrawal of inhaled corticosteroid (ICS) in chronic obstructive pulmonary disease (COPD). We performed a quantitative synthesis in order to assess real impact of ICS discontinuation in COPD patients. Methods We carried out a meta-analysis via random-effects model on the available clinical evidence to evaluate the effect of ICS discontinuation in COPD. Randomized clinical trials and observational real-life studies investigating the effects of ICS withdrawal on the risk of COPD exacerbation, lung function (forced expiratory volume in 1 s [FEV1]) and quality of life (St. George's Respiratory Questionnaire [SGRQ]) were identified by sear…

Pulmonary and Respiratory Medicinemedicine.medical_specialtymedicine.drug_classSocio-culturaleSettore MED/10 - Malattie Dell'Apparato Respiratoriolaw.invention03 medical and health sciencesPulmonary Disease Chronic Obstructive0302 clinical medicineGlucocorticoidQuality of lifeRandomized controlled triallawInhaled corticosteroidForced Expiratory VolumeAdministration InhalationmedicineHumansPharmacology (medical)030212 general & internal medicineIntensive care medicineGlucocorticoidsRandomized Controlled Trials as TopicRespiratory Function TestCOPDInhaled corticosteroidsbusiness.industryChronic obstructive pulmonary diseaseBiochemistry (medical)medicine.diseaseRespiratory Function TestsDiscontinuationrespiratory tract diseasesChronic obstructive pulmonary disease; Inhaled corticosteroids; Withdrawal030228 respiratory systemWithholding TreatmentMeta-analysisRelative riskWithdrawalQuality of LifeCorticosteroidObservational studyChronic obstructive pulmonary disease; Inhaled corticosteroids; Withdrawal; Pulmonary and Respiratory Medicine; Biochemistry (medical); Pharmacology (medical)businessHuman
researchProduct

Severe asthma and COVID-19: lessons from the first wave

2020

Objective: Severe asthma is considered a risk factor for SARS-Coronavirus 2 (SARS-CoV-2) infection but scientific evidences are lacking. Methods: we performed a literature search and review based on PubMed database national, international recommendations as well as papers on severe asthmatic patients and their management during SARS-CoV-2 pandemic. Results: the majority of international recommendations, expert panels and editorials provide indications about management of severe asthmatic patients. No published studies evaluated the effects of biologic agents on severe asthmatic patients during SARS-CoV-2 pandemic. Conclusions: the relationship between SARS-CoV-2 and asthma is variable world…

Pulmonary and Respiratory Medicinesevere asthma2019-20 coronavirus outbreakmedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)biologic agentsvirusesSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Severe asthmaInhaled corticosteroidsSettore MED/10 - Malattie Dell'Apparato Respiratoriooral corticosteroids03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicinemedicineHumansImmunology and AllergyAnti-Asthmatic AgentsPediatrics Perinatology and Child Health030212 general & internal medicineRisk factorskin and connective tissue diseasesPandemicsAsthmabusiness.industryAsthma; biologic agents; COVID-19; inhaled corticosteroids; oral corticosteroids; SARS-CoV-2; severe asthmaSARS-CoV-2fungiPatient AcuityAsthma biologic agents COVID-19 inhaled corticosteroids oral corticosteroids SARS-CoV-2 severe asthmaCOVID-19medicine.diseaseAsthmarespiratory tract diseasesBiologic Agentsbody regions030228 respiratory systemPractice Guidelines as TopicPediatrics Perinatology and Child Healthinhaled corticosteroidsbusiness
researchProduct

Overcoming Barriers to the Effective Management of Severe Asthma in Italy.

2021

Pierluigi Paggiaro,1 Simona Barbaglia,2 Stefano Centanni,3,4 Davide Croce,5 Enrico Desideri,6 Saffi Giustini,7,8 Claudio Micheletto,9 Antonino Musarra,10 Nicola Scichilone,11 Ugo Trama,12 Maria Teresa Zedda,7,13 Giorgio Walter Canonica14 1Department of Surgery, Medicine, Molecular Biology, and Critical Care, University of Pisa, Pisa, Italy; 2Associazione Nazionale Pazienti “Respiriamo Insieme”, Padova, Italy; 3Department of Health Sciences, Università degli Studi di Milano, Milan, Italy; 4Respiratory Unit, ASST Santi Paolo e Carlo, Milan, Italy; 5Center for Health Economics, Social and Health Care Management, LIUC-Università Cattaneo, Castellanza, I…

Pulmonary and Respiratory Medicinesevere asthmaReferralunmet needsSettore MED/10 - Malattie Dell'Apparato Respiratoriooral corticosteroids03 medical and health sciences0302 clinical medicineQuality of life (healthcare)Biologic therapy Expert opinion Oral corticosteroids Severe asthma Unmet needsMultidisciplinary approachHealth careJournal of Asthma and AllergyImmunology and AllergyMedicine0601 history and archaeologybiologic therapyInformation exchange060102 archaeologybusiness.industryMedical record06 humanities and the artsRC581-607medicine.diseaseExpert OpinionIntegrated care030228 respiratory systemMedical emergencyImmunologic diseases. AllergybusinessPatient educationJournal of asthma and allergy
researchProduct

Ocular Drug Delivery Systems per la veicolazione di molecole bioattive al segmento posteriore dell'occhio

Settore CHIM/09 - Farmaceutico Tecnologico ApplicativoBiopolimeri Micelle Polimeriche Scaffold Fibrillari Inserti oftalmici Colliri Corticosteroidi Anti-VEGF Transcorneal Penetration Enhancers Mucoadesione Human Corneal Epithelial Cells Human Retinal Pigment Epithelial Cells Ex Vivo Cornee Bovine Elettrospinning Reattore al Plasma
researchProduct

Use of ICS in COPD: From Blockbuster Medicine to Precision Medicine

2017

Chronic obstructive pulmonary disease (COPD) is a major cause of mortality worldwide, whose burden is expected to increase in the next decades, because of numerous risk factors, including the aging of the population. COPD is both preventable and treatable by an effective management including risk factor reduction, prevention, assessment, and treatment of acute exacerbations and co-morbidities. The available agents approved for COPD treatment are long-acting or ultra-long-acting β2-agonists (LABAs) and long-acting muscarinic antagonists (LAMAs) bronchodilators, as well as inhaled corticosteroids (ICS) in combination with LABAs. ICS use has been restricted only to selected COPD patients by th…

Settore MED/10 - Malattie dell'Apparato RespiratorioAlternative medicineCOPD; drivers; inhaled corticosteroids; prescribing; Pulmonary and Respiratory MedicineCOPD; drivers; inhaled corticosteroids; prescribingAdrenal Cortex HormonePulmonary Disease Chronic Obstructive0302 clinical medicineAdrenal Cortex HormonesDrug Combination030212 general & internal medicinePractice Patterns Physicians'Precision Medicineeducation.field_of_studyCOPDEvidence-Based MedicineprescribingdriversBronchodilator AgentsDrug CombinationsMuscarinic AntagonistPractice Guidelines as TopicGuideline AdherenceHumanAdrenergic beta-2 Receptor AgonistPulmonary and Respiratory Medicinemedicine.medical_specialtydriverPopulationSocio-culturaleInhaled corticosteroidsMuscarinic Antagonistsinhaled corticosteroid03 medical and health sciencesAdministration InhalationmedicineHumansCOPDMedical prescriptionRisk factorIntensive care medicineeducationAdrenergic beta-2 Receptor AgonistsBronchodilator AgentPrimary Health Carebusiness.industryPrecision medicinemedicine.disease030228 respiratory systemObservational studyinhaled corticosteroidsbusiness
researchProduct

Beliefs and preferences regarding biological treatments for severe asthma

2020

Background: Severe asthma is a serious condition with a significant burden on patients' morbidity, mortality, and quality of life. Some biological therapies targeting the IgE and interleukin-5 (IL5) mediated pathways are now available. Due to the lack of direct comparison studies, the choice of which medication to use varies. We aimed to explore the beliefs and practices in the use of biological therapies in severe asthma, hypothesizing that differences will occur depending on the prescribers’ specialty and experience. Methods: We conducted an online survey composed of 35 questions in English. The survey was circulated via the INterasma Scientific Network (INESNET) platform as well as throu…

Severe asthmaBehavior; Belief; Biological drug; Severe asthmainterleukine 5 IgEMULTICENTERDiseaseOmalizumabADD-ON THERAPYBehavior Belief Biological drug Severe asthmaDOUBLE-BLIND0302 clinical medicineMedicine and Health SciencesImmunology and AllergyEosinophil IL5 [Eos]030223 otorhinolaryngologyPulmonologistssevere asthma biological drug belief behavior3. Good healthBeliefSAFETYmedicine.druglcsh:Immunologic diseases. AllergyPulmonary and Respiratory Medicinemedicine.medical_specialtyEos: Eosinophil IL5ImmunologyBiological drugSpecialtylong-acting beta2-agonist OMASocio-culturaleSettore MED/10 - Malattie Dell'Apparato RespiratorioArticle03 medical and health sciencesQuality of life (healthcare)Omalizumab. OMA/IL5 Omalizumab plus anti-IL5 moleculeOMALIZUMABmedicineIntensive care medicineAsthmaBehaviorINterasma Scientific Network LABAbusiness.industryMEPOLIZUMABmedicine.diseaseEFFICACYICS inhaled corticosteroidsLIFE030228 respiratory systemImmunoglobulin E INESNETAllergistslcsh:RC581-607businessMepolizumab
researchProduct

Update on the Management of Pediatric Psoriasis: An Italian Consensus

2022

Introduction Psoriasis affects children with a considerable burden in early life. Treating pediatric psoriasis is challenging also because of the lack of updated specific guidelines. With the recent approval of several biologics for pediatric psoriasis and the ongoing COVID-19 pandemic, the management of young psoriatic patients is facing major changes. A revision of treatment recommendations is therefore needed. Methods In September 2021, a board of six Italian dermatologists convened to update treatment recommendations. The board issued evidence- and consensus-based statements covering relevant areas of pediatric psoriasis, namely: assessment of psoriasis severity, management of children …

Topical corticosteroidsAdolescentBiologicSystemic therapyCorticosteroid-sparingHealth-related quality of lifePediatric psoriasisDermatologyBiologicsAdolescentsPlaque psoriasiAdolescents; Biologics; Children; Corticosteroid-sparing; Health-related quality of life; Pediatric psoriasis; Plaque psoriasis; Systemic therapy; Topical corticosteroidsSettore MED/35Pediatric psoriasiPlaque psoriasisSettore MED/35 - MALATTIE CUTANEE E VENEREEChildren
researchProduct

Effects of a structured educational intervention in moderate-to-severe elderly asthmatic subjects.

2019

Background: Adherence to inhaled drugs is linked to patients’ satisfaction with their device, and an incorrect use can negatively affect the outcomes of asthma treatment. We speculated that this is particularly true in elderly asthmatic subjects. Aim: We performed a national pre-post interventional multicentre study, enrolling moderate-to-severe asthmatic subjects aged ≥65 ​years treated with fixed inhaled combination drugs by dry powder inhaler (DPI) or pressurized metered dose inhaler (pMDI). Adherence and critical errors were evaluated by means of validated questionnaires at first visit (V1) and after 3–6 months (V2). At V1, subjects underwent intensive training on the correct use of the…

Vital capacityACT asthma control testExacerbationSAE severe asthma exacerbationSF12chlorofluorocarbonsmental health composite scoreEDUCA elderly and device use in chronic asthmaPCS physical health composite scoreACT asthma control test; AHDS hospital anxiety depression scale; Asthma; CFC chlorofluorocarbons; Device misuse; EDUCA elderly and device use in chronic asthma; Education; Elderly; FEV1 forced expiratory volume 1s second; FVC forced vital capacity; ICS inhaled corticosteroids; LABA long-acting β2 agonist; LAMA long-acting muscarinic antagonists; MCS mental health composite score; PCS physical health composite score; PROs patient-reported outcomes; SAE severe asthma exacerbation; SF12 short form health survey; mMRC modified medical research councilEDUCAFEV10302 clinical medicineElderlyImmunology and AllergyMedicine030223 otorhinolaryngologybiologymMRC modified medical research councilsevere asthma exacerbationmodified medical research councilLAMASAELamaelderly and device use in chronic asthmaMetered-dose inhalerDry-powder inhalerDevice misusePROs patient-reported outcomesCFCPCSpatient-reported outcomesmMRClcsh:Immunologic diseases. AllergyPulmonary and Respiratory Medicinelong-acting β2 agonistmedicine.medical_specialtyImmunologyLABAphysical health composite scoreArticleLAMA long-acting muscarinic antagonistsAHDSEducation03 medical and health sciencesFEV1/FVC ratiolong-acting muscarinic antagonistsforced vital capacitySF12 short form health surveyAsthma; Device misuse; Education; ElderlyInternal medicineMCS mental health composite scoreforced expiratory volume 1s secondAsthmabusiness.industryFEV1 forced expiratory volume 1s secondInhalerasthma control testbiology.organism_classificationmedicine.diseaseCFC chlorofluorocarbonsACTICS inhaled corticosteroidsFVCAsthmaMCShospital anxiety depression scale030228 respiratory systemICSAHDS hospital anxiety depression scaleFVC forced vital capacityPROsshort form health surveyinhaled corticosteroidslcsh:RC581-607businessLABA long-acting β2 agonistThe World Allergy Organization journal
researchProduct

Effect of an adjunctive first-line intravitreal betamethasone injection in postoperative endophthalmitis

2014

International audience

[SDV.MHEP] Life Sciences [q-bio]/Human health and pathology445 cataract487 corticosteroids[SDV.MHEP.OS] Life Sciences [q-bio]/Human health and pathology/Sensory Organs513 endophthalmitis[SDV.MHEP.OS]Life Sciences [q-bio]/Human health and pathology/Sensory OrgansComputingMilieux_MISCELLANEOUS[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

OCULAR DRUG CARRIERS NANOSTRUTTURATI PER IL TRATTAMENTO DELLE PATOLOGIE DEGENERATIVE DELLA RETINA

Il lavoro di ricerca svolto è stato incentrato sulla preparazione e caratterizzazione di diversi ocular drug carriers nanostrutturati in grado di veicolare molecole bioattive per il trattamento delle retinopatie. Tali sistemi sono stati preparati utilizzando differenti derivati polimerici, ottenuti a partire dall’acido ialuronico (HA) a differente peso molecolare (10-240 kDa). Allo scopo di ottenere micelle polimeriche per la veicolazione di corticosteroidi, sono stati sintetizzati diversi derivati polimerici partendo dall’HA con MW di 10 kDa. Il derivato siglato HAC16b ha mostrato delle caratteristiche vantaggiose, in termini di dimensione, proprietà mucoadesive, valori di drug loading e p…

acido ialuronico micelle polimeriche nanoparticelle polimeriche corticosteroidi imatinib patologie retinicheSettore CHIM/09 - Farmaceutico Tecnologico Applicativo
researchProduct